Highlights from

BCC 2019

St. Gallen International Breast Cancer Conference

Vienna 20-23 March 2019

St. Gallen Consensus - Adjuvant therapy in triple-negative breast cancer

The panellists voted about several questions regarding recommendations for adjuvant chemotherapy in patients with triple-negative breast cancer. All panellists agreed that for patients with pT1a, pN0 (tumour <6 mm), triple-negative breast cancer, chemotherapy is not always indicated; 35% of the panellists took the view that chemotherapy for these patients is never indicated, 65% of the panellists were of the opinion that chemotherapy for these patients is sometimes indicated. In general, the preferred chemotherapy regimen for patients with stage 1 triple-negative breast cancer should contain anthracyclines, alkylators, and taxanes, according to 78% of the panellists, while 50% of the panellists preferred chemotherapy with only alkylators and taxanes in case a stage 1 triple-negative breast cancer patient has a tumour with a size ≤1 cm. For patients with stage 2 triple-negative breast cancer, almost all panellists (94%) were in favour of a chemotherapy regimen containing anthracycline, alkylator, and taxane.

The content and interpretation of these conference highlights are the views and comments of the speakers/authors.